Colorectal tumors are continuously exposed to an inflammatory environment, which together with mitogenic signals sustain several cancer hallmarks. Nuclear factor-kappa B (NFκB) is a major regulator of inflammation and variation in NFκB-associated genes could potentially be used as biomarkers to identify patients with increased risk of colorectal cancer (CRC) development, and/ or a rapidly progressing disease. In this study, 348 CRC cases and 806 randomly selected healthy individuals from southeastern Sweden were examined with regard to seven polymorphisms in NFκB pathway-associated genes. Log-rank-tests and Cox proportional hazard regression analysis examined the association between the polymorphisms and CRC-specific survival, whereas chi-square tests and logistic regression analysis were used to test for associations between the polymorphisms and CRC susceptibility. Gene expression and loss of heterozygosity analyses of TNFAIP3 were carried out in a subset of tumors to assess its role as a tumor suppressor in CRC. Heterozygous and polymorphic TNFAIP3 (rs6920220), heterozygous NLRP3 (Q705K) and polymorphic NFκB -94 ATTG ins/del genotypes were found to be associated with poorer survival in patients diagnosed with invasive CRC (aHR = 5.2, 95% CI: 2.5-10.9, P < 0.001). TNFAIP3 mRNA levels were significantly decreased in tumors compared with adjacent non-neoplastic mucosa (P < 0.0001) and loss of heterozygosity of 6q23.3 (TNFAIP3) was detected in 17% of cases, whereas only 2.5% of the investigated specimens displayed TNFAIP3 gene mutations. We propose that TNFAIP3 (rs6920220), NLRP3 (Q705K) and NFκB -94 ATTG ins/del polymorphisms are associated with poor survival in patients with advanced CRC and may be used as prognostic markers. Experimental results indicate that TNFAIP3 may act as a tumor suppressor in CRC.
Introduction
Although for long poorly elucidated, a link between cancer and inflammation was early suspected due to pathological and clinical observations where the conditions seemed to commonly coexist. Following the last decades of intense research and ever growing possibilities to experimentally investigate the cellular and molecular biology behind both inflammation and cancer, Hanahan and Weinberg recently took the next step and proposed tumor-promoting inflammation as an enabling characteristic of tumors in addition to their previously stated 'Hallmarks of Cancer' (1) .
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths with about 1.2 million new worldwide cases diagnosed each year (2) . Chronic inflammatory bowel diseases (IBDs), e.g. Crohn's disease (CD) and ulcerative colitis (UC), strongly increase the risk of 'colitis-associated cancer' (CAC) (3) . However, the molecular mechanisms linking inflammation and 'sporadic' CRC are poorly understood, although it is generally believed that the inflammatory response follows tumor initiation (rather than the opposite) in the sporadic cases (3, 4) . The importance of cancer-related inflammation is further emphasized by recent studies which reveal that tumor growth and progression depend on the activation of nuclear factor-kappa B (NFκB), a key controller of the innate immune response, both in the intestinal epithelium and in infiltrating inflammatory cells (3) (4) (5) . NFκB signaling in epithelial cells is evoked by a variety of signals, including the release of reactive oxygen or nitrogen species (RONS), presentation of antigens to the cell or through binding of cytokines, such as TNFα, IL-6 or IL-1β to their respective membrane receptors (reviewed in Hymowitz (6)). Major activators of canonical NFκB signaling are the Toll-like/interleukin-1 receptor family (TLR, IL-1R) and the tumor necrosis factor (TNF) receptor, which are activated on binding of lipopolysaccharide (TLR4), IL-1 (IL-1R) or TNFα (TNF receptor ) (6) . The receptor binding and subsequent pathway signaling lead to activation of the IκB kinase (IKK) complex comprising of IKKγ/NEMO, IKKα and IKKβ, which is followed by the phosphorylation and subsequent ubiquitination and proteasomal degradation of IκBs. Ultimately, liberated NFκB translocates to the nucleus and activates several proinflammatory and antiapoptotic genes through direct interference with the DNA transcription machinery (3, 4) . Genetic explanation for aberrant NFκB activation in CRC is sparse, but in two separate studies individuals carrying the deletion allele of the functional -94 ATTG insertion/deletion (ins/del) polymorphism in the promoter region of NFκB were found to carry an increased risk of CRC in Swedish (7) and Danish (8) populations. Polymorphisms in the genes encoding TLRs and ILR ligands were described previously to be associated with the risk of various cancer forms, including CRC (9) (10) (11) (12) (13) (14) .
NFκB signaling is under control of TNFAIP3 (also known as A20) encoded by the TNFAIP3 gene on chromosome 6q23.3, a 790 amino acid protein with ubiquitin editing properties. It removes ubiquitin moieties via its ovarian tumor domain whereas the C-terminal zinc fingers (ZnF; mainly ZnF4) provide E3 ligase activity (15) . TNFAIP3 disrupts NFκB activation via several mechanisms of which the most well-described consists of a series of ubiquitination and deubiquitination steps of several NFκB-associated proteins that ultimately terminates NFκB activity (6, 15, 16) . On the other hand, the expression of TNFAIP3 is regulated by NFκB (17) , which in a negative feedback loop manner serves to terminate NFκB activation. TNFAIP3 deficient mice develop severe inflammation in multiple organs, including the intestines where the loss of epithelial integrity is thought to evoke the strong inflammatory response that is observed (18, 19) . Similarly, TNFAIP3 expression was decreased in the intestines of CD patients, a disease where the epithelial integrity is thought to be severely damaged (20) . The proposed roles of TNFAIP3 in cancer are diverse and most probably dependent on the cellular context. Although the knowledge on this issue is still limited, a few studies report some interesting clinical findings. Although undifferentiated head and neck squamous cell carcinomas, nasopharyngeal carcinomas (21), estrogen receptor negative breast cancer (22) and glioblastoma stem cells (23) , show overexpression of TNFAIP3, decreased TNFAIP3 levels have very recently been found in pancreatic cancers (24) and a tumor suppressive role has been proposed in B-cell lymphomas (25, 26) . Moreover, several single nucleotide polymorphisms (SNPs), including rs6920220, in TNFAIP3 were connected with increased risk of rheumatoid arthritis (27, 28) , IBD (29) , psoriasis (30) and type 1 diabetes (31), enlightening the importance of the gene in common inflammatory/autoinflammatory disorders.
Other molecular networks take part in NFκB-driven inflammation, such as the recently described NLRP3 inflammasome, a multiprotein complex consisting of NLRP3 (also called CIAS1 and NALP3), ASC, CARD8 and procaspase-1. Although the exact role of CARD8 in the inflammasome is a debatable issue, its role as an inhibitor of NFκB and caspase-1 is more well-understood (32, 33) . Assembly of the NLRP3 inflammasome is triggered by danger-associated molecular patterns and results in activation of procaspase-1 to caspase-1, which converts proIL-1β to mature and active IL-1β (34) . Germline mutations in the NLRP3 gene are associated with various inflammatory diseases and familial periodic fever syndromes, e.g. cryopyrin-associated periodic syndromes. SNPs in the NLRP3 gene and a nonsense polymorphism (C10X) in CARD8 have been associated with susceptibility to CD in men (35) , whereas their role in intestinal malignancy, to our knowledge, has not yet been investigated.
In this study, enrolling 348 Swedish CRC patients and ~800 healthy controls, we reveal that variations in genes being involved in the NFκB/TNFAIP3-and NLRP3-mediated inflammation are associated with the susceptibility and/or outcome of CRC. Further, we suggest that TNFAIP3 is a potential tumor suppressor in CRC, displaying loss of heterozygosity (LOH) in 17% of the investigated cases. Mutational inactivation is another hypothetical 'hit' to the TNFAIP3 gene, but was found to be a rare event in the investigated material. This is, to our knowledge, the first study that investigates and identifies a correlation between TNFAIP3 (rs6920220) and NLRP3 (Q705K) SNPs and the survival of CRC patients.
Materials and methods
Patient material, DNA and RNA isolation Clinical information, including age and gender, Dukes' staging, polypoid/ ulcerative phenotype and survival data, was obtained from the Swedish Cancer register for 355 patients with sporadic CRC undergoing surgical resection between 1998 and 2005 at the County Hospital Ryhov, Jönköping and University Hospital, Linköping, Sweden. Normal intestinal mucosal biopsies resected ~10 cm from the tumor (n = 235) and/or normal blood samples (n = 223) were collected from 348 of these patients. All patients underwent surgery and the tumor tissue was saved, examined and diagnosed by experienced pathologists at respective hospitals. About 806 randomly selected healthy individuals within the same geographical area as the CRC patients were collected during the years 1998 to 2000 and used as controls in this study. Tissue and blood samples were immediately snap frozen and stored at -70°C until nucleic acid isolation. Genomic DNA was isolated from the tissue and normal blood samples with the Wizard® Genomic DNA Purification Kit (Promega, Madison, WI) according to the supplier's recommendations. Total RNA was isolated from intestinal tumor tissue and corresponding non-neoplastic mucosa using Illustra TM triplePrep kit (GE Healthcare, Buckinghamshire, UK) or RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer's recommendations. The study was approved by the Research Ethics Committee at the Faculty of Health Sciences, Linköping (Dnr. 98113).
SNP selection and real-time PCR TaqMan® SNP genotyping
One aim of the study was to determine and evaluate the role of polymorphisms in genes linked to NFκB pathway-mediated inflammation as susceptibility factors for sporadic CRC. The investigated genes, SNPs and their genotyping assays can be found in Supplementary , which was performed with the TaqMan® Fast Universal PCR Master Mix (Applied Biosystems) and cDNA-specific primer/probe mixes for TNFAIP3 (Hs00234713_m1) (Applied Biosystems). The relative concentrations of TNFAIP3 were normalized to the expression of the control genes β-glucuronidase (GUSB) (4333767F) and cyclophilin A (PPIA) (4333763T) (Applied Biosystems).
Loss of heterozygosity analysis of 6q23.3
Six microsatellite markers, one trinucleotide ins/del polymorphism and one SNP were chosen for LOH mapping of an ~2.8 Mb region of chromosome 6q23.3 (including the TNFAIP3 gene). The marker information, primer sequences and PCR conditions are listed in Supplementary Table 2 , available at Carcinogenesis Online. The order of these markers was as follows: centromere-D6S292-D6S1009-rs6920220-D6S(1381118)-rs5029940-D6S(1382694)-D6S1587-D6S1569-telomere, where D6S(1381118) and D6S(1382694) are previously unreported dinucleotide repeats [chromosomal positions in hb (hectobases) within brackets] and rs5029940 is an TNFAIP3 intragenic trinucleotide ins/del polymorphism. LOH analysis of the microsatellite markers and the trinucleotide repeat were carried out using fluorescently tagged primers and two pools of multiplex-PCR (Supplementary Table 2 , available at Carcinogenesis Online). About 1 µl of diluted PCR product was combined with 0.3 µl of Genescan LIZ 600 size standard (Applied Biosystems) and 12 µl of formamide loading buffer (HiDi) (Applied Biosystems) and analyzed on a ABI 3500 Genetic Analyzer (Applied Biosystems). GeneMapper v.4.1 (Applied Biosystems) was used to determine size, height and area for each detected fluorescent peak. Alleles were defined as the two highest peaks within the expected size range and a tumor/normal ratio (T1:T2/N1:N2) was used to determine LOH. The ΔΔC t method was used to determine LOH for the rs6920220 SNP. Allelic loss of ≥35% (ratio of 0.65 or 1.54) for both peak height and area was scored as LOH for a single marker.
Mutational analyses of TNFAIP3
A detailed description of the mutational analyses of TNFAIP3 can be found in Supplementary Methods.
Statistical analysis and figure composition
Standard chi-square test was used to test genotype frequencies for Hardy-Weinberg equilibrium. Associations between genotype and disease risk were assessed by calculating odds ratios (OR) and corresponding 95% confidence intervals (CI). Linkage disequilibrium between polymorphisms of the TLR4 gene was examined by pair-wise comparisons of D′-values and the correlation coefficient (r 2 ) using HaploView version 4.1 (Broad Institute of MIT and Harvard, Boston, MA). For survival analysis Kaplan-Meier curves were generated and tested for significance by the log-rank test. Overall, survival was the time elapsed from diagnosis of CRC to the date of death, whereas CRC-specific survival was the time elapsed from diagnosis to the date of death from CRC. The median follow-up time after diagnosis was 56 months. Cox proportional hazard modeling was used to estimate hazard ratios and corresponding P values, associated with the polymorphisms. Crude hazard ratios (cHRs) for NFκB -94 ATTG ins/del, TNFAIP3 (rs6920220) or NLRP3 (Q705K) genotypes, gender, age and phenotypes were determined independently. Adjusted hazard ratios (aHR) analyses of NFκB -94 ATTG ins/del, TNFAIP3 (rs6920220) or NLRP3 (Q705K) genotypes on CRC-specific survival of patients in the Dukes' C+D group included gender, age and polypoid/ulcerative phenotype and these were calculated to investigate simultaneous effects and generalizability of the factors investigated. Group comparisons for the mRNA expression analyses were performed using Mann-Whitney U-tests and Wilcoxon Rank-Sum tests. Error bars display the interquartile range (IQR).
Statistical analysis was performed with SPSS Statistics 18 (IBM Corporation, Somers, NY), Graphpad Prism 5 (GraphPad Software, San Diego, CA) and Stata 11 (StataCorp LP, Lakeway Drive, TX). P < 0.05 were considered as statistically significant.
Results

NFκB -94 ins/del ATTG, TNFAIP3 (rs6920220) and NLRP3 (Q705K) SNPs are associated with Dukes' stage-related survival
Survival data were available for 348 patients, but normal DNA was only available for 337 of these, which were included in the following analyses. For each SNP, patients were stratified according to their specific genotypes except for TLR4 (D299K) and TLR4 (T399I), which were combined according to their haplotypes: G-T (polymorphic alleles) in one group and A-C, A-T and G-C in the other. No significant differences in CRC-specific survival could be identified (Supplementary Figure 1 , available at Carcinogenesis Online), neither could we detect any differences in overall survival between the different genotypes for the investigated SNPs (Supplementary Figure 2 , available at Carcinogenesis Online).
Exploratory subgroup analyses
Subgroup analysis revealed differences in CRC-specific survival between the NFκB -94 ins/del ATTG, TNFAIP3 (rs6920220) and NLRP3 (Q705K) genotypes when stratification for Dukes' stages A+B and C+D was considered. A log-rank test showed no significant differences within the A+B group for any of the polymorphisms ( Figure 1A-C) . Among the C+D patients the del/del genotype of NFκB -94 ins/del ATTG led to significantly shorter CRC-specific survival (P = 0.007) ( Figure 1D ). Patients homozygous for the AA genotype of TNFAIP3 (rs6920220) had a significantly shorter CRC-specific survival compared with carriers of the GG genotype (P = 0.001) ( Figure 1E ). Individuals with a NLRP3 (Q705K) CA genotype in the C+D group had likewise a significantly shorter CRC-specific survival (P = 0.004) ( Figure 1F) . Furthermore, the ulcerative phenotype was found to be significantly associated with poorer CRC-specific survival (cHR = 2.1, 95% CI: 1.0-4.3, P = 0.04) (Supplementary Figure 3A , available at Carcinogenesis Online), but not overall survival (P = 0.2) (Supplementary Figure 3B , available at Carcinogenesis Online), which is in concordance with a previous study by Nasir et al. (36) .
A multivariate Cox regression analysis was carried out to evaluate the potential prognostic significance of NFκB -94 ATTG ins/ del, TNFAIP3 (rs6920220) and NLRP3 (Q705K) polymorphisms on CRC-specific survival of patients in the Dukes' C+D group. The multivariate models included SNP genotypes, gender, age and polypoid/ulcerative phenotype. The NFκB -94 ATTG ins/del, TNFAIP3 (rs6920220) and NLRP3 (Q705K) polymorphisms were statistically significant in these models, with the heterozygous or/and polymorphic genotypes being significantly associated with poorer CRC-specific survival if diagnosed with Dukes' stage C+D, but not Dukes' stage A+B (Table II) any of the polymorphic variants of these polymorphisms within the Dukes' C+D group have a poorer survival, we defined a so-called prognostic panel of the polymorphisms with significant genotypes in the multivariate Cox regression models (Table II) . The prognostic panel consists of NFκB -94 ATTG ins/del, TNFAIP3 (rs6920220) and NLRP3 (Q705K) and results in cHR of 2.9 (95% CI: 1.7-5.1, NFκB/TNFAIP3-and NLRP3-inflammasome signaling in colorectal cancer P < 0.001, n = 110) (Table II) with a worse prognosis for carriers of the polymorphic and/or heterozygous genotypes. Adjusting for age, gender and polypoid/ulcerative phenotype the panel stays significant (prognostic panel: aHR = 5.2, 95% CI: 2.5-10.9, P < 0.001, n = 75) (Table II) . Altogether, the homozygous polymorphic NFκB -94 ATTG ins/del variant, the heterozygous and homozygous polymorphic TNFAIP3 (rs6920220) variants and heterozygous variant of NLRP3 (Q705K) are associated with poor survival in CRC patients diagnosed with advanced CRC.
NFκB pathway SNPs and colorectal cancer susceptibility
Distribution of the SNP genotypes in the study populations and the ORs for developing CRC are summarized in Table III . All the polymorphisms were found to be in Hardy-Weinberg equilibrium in the control population. TLR4 D299K and TLR4 T399I were found to be in tight linkage disequilibrium (D′ = 0.9, r 2 = 0.7), with the polymorphic (minor) alleles in phase. Heterozygosity for NFκB -94 ins/del ATTG was significantly associated with CRC susceptibility when compared with homozygous wild-type allele (ins/ins) carriers (OR = 1.6, 95% CI: 1.2-2.1, P = 0.003). No other significant associations were identified regarding the investigated polymorphisms and CRC susceptibility, although the NLRP3 (rs10733113) AA genotype showed borderline significance (OR = 2.2, 95% CI: 1.0-5.2, P = 0.07) (Table  III) . To investigate a potential SNP combinatorial risk increase for the development of CRC, multiple logistic regression analysis was carried out on combinations of polymorphisms in the patient and control material. A moderate, however, non-significant risk increase was seen when combining NLRP3 (Q705K) and CARD8 (C10X) for the CA and TA genotypes (OR = 1.7, 95% CI: 1.0-2.9, P = 0.08). A similar trend was observed when combining patients with one or more variant alleles for each SNP (OR = 1.6, 95% CI: 1.0-2.6, P = 0.08) (Supplementary Table 3 , available at Carcinogenesis Online).
TNFAIP3 gene expression is downregulated in colorectal tumors
To determine whether TNFAIP3 expression levels were significantly altered in colorectal malignancies, total RNA was isolated from 57 CRC/non-neoplastic colorectal pairs and additional 12 tumor tissue samples and analyzed by quantitative RT-PCR. Significantly lower TNFAIP3 mRNA levels were found in the tumors as compared with adjacent non-neoplastic intestinal mucosa (Mann-Whitney U-test, P < 0.0001, paired Wilcoxon Rank-Sum test, P < 0.0001) (Figure 2A ; Supplementary Table 3 , available at Carcinogenesis Online). Moreover, TNFAIP3 expression levels in normal intestinal mucosa correlated with TNFAIP3 (rs6920220) genotype status. Homozygous wild-type individuals (GG) displayed ~1.7-fold higher mRNA expression compared with GA+AA individuals (Mann-Whitney U-test, P = 0.016) indicating a gene dose-dependent expression.
The TNFAIP3 gene is frequently deleted in colorectal adenocarcinomas, leading to lower gene expression
Further, we elucidated potential mechanisms underlying the decreased TNFAIP3 mRNA levels seen in the tumors. TNFAIP3 is frequently lost in follicular lymphoma due to LOH of 6q23.3 (37) . Using eight markers spanning the region 6q23.3, 25 out of 149 CRC tumors (16.8%) showed LOH and of these 25 out of 20 cases showed continuous loss of the entire analyzed region (2.8 Mb), whereas 5 cases showed loss of a smaller part (0.42 Mb), however, still encompassing TNFAIP3. Figure 2B displays how the markers are located on the chromosome 6q in relation to TNFAIP3 and also a representative sample showing LOH for five out of eight markers (rs6920220 is left out of Figure 2B ). LOH was associated with decreased TNFAIP3 mRNA expression (Mann-Whitney U-test, P = 0.0033) at least partly explaining the lower expression levels seen in the CRC tumors ( Figure 2C ; Supplementary Table 3, available at Carcinogenesis Online).
The TNFAIP3 gene is rarely mutated in colorectal adenocarcinomas
Using single-stranded conformation analysis (SSCA) mutational screening and subsequent DNA sequencing, mutations in TNFAIP3 were detected in 2 out of 79 colorectal tumors (2.5%). In one case, a missense mutation c.305A>G (p.N102S) with germline origin was found (Supplementary Figure 5A , available at Carcinogenesis Online). The substitution occurred one amino acid prior to the catalytic residue of the ovarian tumor deubiquitinase domain. The asparagine residue and the adjacent protein sequence are evolutionary conserved, implying a functional importance (Supplementary Figure 5B , available at Carcinogenesis Online). A second mutation in exon 9 in an unrelated sample uncovered the deletion of one nucleotide: c.2274delC. Sequencing of corresponding DNA from normal intestinal mucosa proved the mutation to be somatic Supplementary Figure 5C , available at Carcinogenesis Online). The mutation results in a prolonged protein p.K759Sfs*57X and a complete ablation of the evolutionary conserved ZnF7 domain (Supplementary Figure 5D , available at Carcinogenesis Online). Interestingly, this mutation was found in a microsatellite instable tumor (data not shown), however none of the two mutated samples showed any signs of LOH. Multiple sequence alignment of TNFAIP3 in silico with ClustalX v2.1 revealed that the ovarian tumor and ZnF7 domains are conserved among species. The identified c.305A>G germline mutation is not entered into the NCBI dbSNP database, but has previously been found in patients with B-cell lymphoma (25, 38) . We, therefore, investigated whether TNFAIP3 c.305A>G is a common genetic variant among CRC patients or healthy control individuals. Using PCR-RFLP (Supplementary Table 4 , available at Carcinogenesis Online) and subsequent gel electrophoresis, 342 CRC cases and 365 control individuals were tested for c.305A>G in their normal DNA (either blood or normal intestinal tissue). The assay was verified using the previously identified mutants as positive controls. No additional mutations were found implying that TNFAIP3 c.305A>G is a rare genetic variant.
Discussion
It is commonly known that even though acute inflammation is essential for the host's microbe defense and tissue repair, a chronic inflammatory condition degenerates the tissue, increases the risk of sustained cell and DNA damage and promotes tumor formation and progression. This is clearly evident in patients with IBD, who suffer an increased risk of CRC and especially CAC (3). A widely accepted link between inflammation and CRC is underlined by studies of the proinflammatory NFκB pathway, which promotes cell proliferation, inhibits apoptosis (4) and is found activated in primary and metastatic CRC (39) . An ATTG (ins/del) polymorphism in the NFκB promoter has been associated with increased risk of CRC (7, 8) . Consistent with these findings, we found an increased risk of CRC in individuals heterozygous for the ins/del genotype. The deletion allele has been associated with lower gene expression in vitro (40) , which intuitively is associated with a poorer inflammatory response. However, Greten et al. (41) unexpectedly discovered that NFκB also could function as a negative posttranslational regulator of IL-1β secretion through caspase-1 independent but serine protease-dependent pathways, possibly in an inflammation stage-dependent manner emphasizing an even more complex role of NFκB in regulating inflammation. In the survival analysis, no association of the NFκB -94 ATTG ins/del polymorphism with CRC-specific or overall survival was found, which is in accordance with a previous study by Riemann et al. (42) . However, stratification for Dukes' stages A+B and C+D revealed a poorer survival for patients carrying the del/del genotype among the C+D patients ( Figure 1A and 1D and Table II) . A CRC-specific survival 
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analysis comparing the A+B and C+D groups verifies a poorer survival in the C+D group (P < 0.001) (Supplementary Figure 3C , available at Carcinogenesis Online) and justifies the crude subgrouping. The rs6920220 SNP is located in a putative TNFAIP3 regulatory region ~185 kb upstream of the gene. Corroborating previous epidemiological and functional studies (27, 28, 43) , we show that the variant allele of the rs6920220 SNP on TNFAIP3 associates with a lower TNFAIP3 expression in non-neoplastic intestinal tissue as compared with the wild-type G-allele. Due to TNFAIP3 inhibitory effects on NFκB signaling, a hypomorphic TNFAIP3 gene will probably contribute to the NFκB activation seen in primary and metastatic CRC (39) . After adjusting for gender, age and polypoid/ulcerative phenotypes, the association with poorer survival remained highly significant, suggesting that TNFAIP3 (rs6920220) may be a novel prognostic marker in patients with advanced stages of CRC. To our knowledge, the findings in this study are the first to suggest a tumor suppressive role for TNFAIP3 in CRC. Previously, Arsenescu et al. (20) reported decreased TNFAIP3 expression in intestinal tissue from CD patients and here we suggest that low levels of functional TNFAIP3 in a similar manner may be connected with colorectal malignancy. Hypothetically, loss of TNFAIP3 in intestinal epithelial cells may be an event contributing to a chronic/dysfunctional inflammatory response with chronic uncontrolled NFκB activation, which may foster a tumor. In the present material, TNFAIP3 mRNA levels were found to be significantly lower in tumors compared with the adjacent non-neoplastic mucosa (Figure 2A ) supporting the before-mentioned hypothesis.
TNFAIP3 is located on chromosome 6q23.3, a region frequently deleted in various cancer forms (37, 44, 45) and the suggested tumor suppressor function of TNFAIP3 in B-cell lymphomas and lower TNFAIP3 expression seen in the colorectal tumors prompted us to do LOH analysis of the 6q23.3 region. In total, LOH was detected in 25 out of 149 CRC tumors (16.8%), which also was associated with a significantly lower gene expression ( Figure 2C ). Interestingly, loss of 6q23.3 is a relatively frequent event in sporadic CRC and this chromosomal region contains several additional tumor suppressor candidates and genes involved in the inflammatory response, e.g. BCLAF1, MAP3K5, IL-22Rα2 and IFNγR1 that may be responsible or contributing factors in addition to LOH of TNFAIP3. A possible tumor suppressive role for TNFAIP3 in CRC is further underlined by the single somatic and germline mutations identified in this study. Both identified mutations are located in evolutionary well-conserved domains (Supplementary Figure 5B and D, available at Carcinogenesis Online), which may affect the function of the protein. The c.2774delC mutation alters the whole ZnF7 domain, which is important for the role of TNFAIP3 as an inhibitor of NFκB. The TNFAIP3 N102S mutation was reported previously in three B-cell lymphomas (25, 38) and at least once unambiguously identified as a germline alteration. Together with our data, this proposes that TNFAIP3 N102S may be a germline genetic variant that predisposes for cancers that are characterized by increased inflammatory NFκB activity. Collectively, our results suggest that an increased NFκB activity, at least partly, could be explained by allelic loss of one copy of TNFAIP3 and/or the lowexpressing TNFAIP3 (rs6920220) A-allele. In combination with the lower TNFAIP3 expression seen in the tumors, this proposes a tumor suppressive function of TNFAIP3 in CRC. Similar with TNFAIP3 (rs6920220), we find an association between heterozygous NLRP3 (Q705K) and poor patient survival in advanced tumors (Dukes' C+D) and to our knowledge this is the first study that reports an association between SNPs in the NLRP3 gene and CRC patient survival. These results, together with the lack of association of these SNPs with CRC susceptibility or patient survival in the Dukes' A and B group, support a model where these inflammatory signals rather contribute to late-stage sporadic colorectal tumorigenesis than early as often is the case in CAC (3). The Q705K SNP is quite prevalent in the healthy population and has been associated with increased risk of rheumatoid arthritis and Crohn's disease (35, 46, 47) and most recently with malignant melanoma (48) . In a recently published study by our group using the monocytic cell line THP-1, we have demonstrated that the Q705K in NLRP3 leads to an increased production of IL-1β and IL-18 (49) . This gain of function polymorphism, in combination with other triggering factors might contribute to an increased predisposition toward inflammatory conditions. Studies of CAC-affected mice with inducible NLRP3 deficiency reveal a protective role for the NLRP3 inflammasome against colitis and CAC (50,51). This protective role has been attributed to NFκB and NLRP3-inflammasome-regulated cytokine IL-18 production, which plays a pivotal role in the repair of ulcerated epithelium during the acute inflammatory phase and has also been proposed to have antitumorigenic effects (51) . These results suggest that in the acute inflammatory phase during the early formation of intestinal adenomas, the NLRP3 inflammasome may have a protective role, but if overactivated it may contribute to chronic inflammation and in more advanced sporadic CRC cases, lead to poorer survival.
Both overactivation of the NLRP3 inflammasome and downregulation or genetic alterations in TNFAIP3, may contribute to increased IL-1β and subsequent IL-6 levels and a poorer outcome for the CRC patient. As an adjuvant to standard cancer treatment, IL-1β or IL-6 blocking therapy has been proposed to alleviate inflammation and tumor progression in advanced CRC. We acknowledge that the significance of the observed associations for susceptibility and survival may not survive stringent correction for multiple testing. However, due to the explorative nature of this study, we purposely did not correct for multiple comparisons so as not to eliminate potentially important results. Therefore, the data should be interpreted with some caution and we would welcome independent replications of this study as well as further functional analyses of the polymorphisms herein enrolled.
In conclusion, we here suggest that the anti-inflammatory gene TNFAIP3 may act as a novel tumor suppressor in CRC and, further, that a panel of SNPs in genes being involved in inflammation pathways, i.e. rs6920220 in TNFAIP3, Q705K in NLRP3 (rs35829419) and NFκB -94 ATTG ins/del (rs28362491) polymorphism could be used as prognostic markers to identify patients at high risk of rapid CRC progression and poor survival. Our results highlight the crucial role of the investigated inflammation pathways in advanced/terminal stages of sporadic CRC rather than in early stages. Speculatively, analyses of inflammation-associated genes may aid in identifying patients for future IL-and/or NFκB-modulating therapies.
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